1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348 (13): 1201-1214.
2. NMPN Study Group. Guidelines for the diagnosis and treatment of eosinophilia. 2nd version, September 2012, www.nordicmpd.org. :4.
3. Havelange V, Demoulin J-B. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with eosinophilia. Journal of Blood Medicine 2013; 4: 111-121.
4. Jawhar M, Naumann N, Schwaab J, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic and blast phase. Annals of Hematology 2017; 96 (9): 1463-1470.
5. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood 2017; 129: 704-714.
6. Chase A, Bryant C, Score J, Cross NC. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 2013; 98 (1): 103-106.
7. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65 (7): 2662-2667.
8. Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 2014; 166 (6): 809-817.
9. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391-2324.
10. Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2891.
11. Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the Unites States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010; 126: 179-181.
12. Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012; 5 (2): 157-176.
13. Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 2014; 89: 325-337.
14. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347 (7): 481-487.
15. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103 (2): 473-478.
16. Muller AM, Martens UM, Hofmann SC, et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006; 85: 1-16.
17. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92 (9): 1173-1179.
18. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion-gene positive and BCRABL- negative chronic myeloproliferative disorders. Blood 2007; 109: 61-64.
19. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109 (11): 4635-4640.
20. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124 (6): 1319-1325.
21. Klion AD. How I treat hypereosinophilic syndromes. Blood 2009; 114: 3736-3741.
22. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010; 85 (2): 158-164.
23. Helbig G, Moskwa A, Hus M, et al. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Hematol Oncol 2010; 28 (2): 93-97.
24. Bochner BS, Gleich GJ. What targeting eosinophils has taught us about their role in disease. J Allergy Clin Immunol 2010; 126: 16-25.